Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy.
Rovira J, Valera A, Colomo L, Setoain X, Rodríguez S, Martínez-Trillos A, Giné E, Dlouhy I, Magnano L, Gaya A, Martínez D, Martínez A, Campo E, López-Guillermo A. Rovira J, et al. Among authors: dlouhy i. Ann Hematol. 2015 May;94(5):803-12. doi: 10.1007/s00277-014-2271-1. Epub 2014 Dec 14. Ann Hematol. 2015. PMID: 25501975 Free PMC article.
MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome.
Rovira J, Karube K, Valera A, Colomer D, Enjuanes A, Colomo L, Martínez-Trillos A, Giné E, Dlouhy I, Magnano L, Delgado J, Martínez A, Villamor N, Campo E, López-Guillermo A. Rovira J, et al. Among authors: dlouhy i. Clin Cancer Res. 2016 Jun 1;22(11):2755-64. doi: 10.1158/1078-0432.CCR-15-1525. Epub 2016 Jan 20. Clin Cancer Res. 2016. PMID: 26792260
High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma.
Dlouhy I, Filella X, Rovira J, Magnano L, Rivas-Delgado A, Baumann T, Martínez-Trillos A, Balagué O, Martínez A, González-Farre B, Karube K, Gine E, Delgado J, Campo E, López-Guillermo A. Dlouhy I, et al. Leuk Res. 2017 Aug;59:20-25. doi: 10.1016/j.leukres.2017.05.014. Epub 2017 May 17. Leuk Res. 2017. PMID: 28544905
Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma.
Magnano L, Balagué O, Dlouhy I, Rovira J, Karube K, Pinyol M, Rivas-Delgado A, Costa D, Martínez-Trillos A, González-Farre B, Martínez-Pozo A, Giné E, Colomer D, Delgado J, Villamor N, Campo E, López-Guillermo A. Magnano L, et al. Among authors: dlouhy i. Ann Oncol. 2017 Nov 1;28(11):2799-2805. doi: 10.1093/annonc/mdx407. Ann Oncol. 2017. PMID: 29045517 Free article. Clinical Trial.
Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era.
Rivas-Delgado A, Magnano L, Moreno-Velázquez M, García O, Nadeu F, Mozas P, Dlouhy I, Baumann T, Rovira J, González-Farre B, Martínez A, Balague O, Delgado J, Villamor N, Giné E, Campo E, Sancho-Cia JM, López-Guillermo A. Rivas-Delgado A, et al. Among authors: dlouhy i. Br J Haematol. 2019 Mar;184(5):753-759. doi: 10.1111/bjh.15708. Epub 2018 Dec 4. Br J Haematol. 2019. PMID: 30515755 Free article. Clinical Trial.
54 results